Advertisement

Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer

  • Peter A. FaschingEmail author
  • Paul Gass
  • Lothar Häberle
  • Bernhard Volz
  • Alexander Hein
  • Carolin C. Hack
  • Michael P. Lux
  • Sebastian M. Jud
  • Arndt Hartmann
  • Matthias W. Beckmann
  • Dennis J. Slamon
  • Ramona Erber
Clinical Trial
  • 48 Downloads

Abstract

Purpose

Several clinical trials have investigated the prognostic and predictive usefulness of molecular markers. With limited predictive value, molecular markers have mainly been used to identify prognostic subgroups in which the indication for chemotherapy is doubtful and the prognosis is favorable enough for chemotherapy to be avoided. However, limited information is available about which groups of patients may benefit from additional therapy. This study aimed to describe the prognostic effects of Ki-67 in several common subgroups of patients with early breast cancer.

Methods

This retrospective study analyzed a single-center cohort of 3140 patients with HER2−, hormone receptor-positive breast cancer. Five-year disease-free survival (DFS) rates were calculated for low (< 10%), intermediate (10–19%), and high (≥ 20%) Ki-67 expression levels, as assessed by immunohistochemistry, and for subgroups relative to age, body mass index, disease stage, tumor grade, and (neo-)adjuvant chemotherapy. It was also investigated whether Ki-67 had different effects on DFS in these subgroups.

Results

The 5-year DFS rates for patients with low, intermediate, and high levels of Ki-67 expression were 0.90, 0.89, and 0.77, respectively. Ki-67 was able to further differentiate patients with an intermediate prognosis into different prognostic groups relative to common clinical parameters. Patients with stage II breast cancer had 5-year DFS rates of 0.84, 0.88, and 0.79 for low, intermediate, and high levels of Ki-67 expression. Ki-67 had different prognostic effects in subgroups defined by age and tumor grade.

Conclusions

Ki-67 may help identify patients in intermediate prognostic groups with an unfavorable prognosis who may benefit from further therapy.

Keywords

Breast cancer Ki-67 Proliferation Molecular marker Prognosis 

Notes

Compliance with ethical standards

Conflict of interest

AH has received honoraria from Roche, Janssen, Merck Sharp Dome, AstraZeneca, Novartis, Cepheid, Abbvie and Boehringer-Ingelheim. His institution performs research with Grants from Biontech, Janssen, Cepheid, Roche and Qiagen. DJS has received honoraria from Novartis, Pfizer and Lilly and owns stock in Pfizer, Amgen and Seattle Genetics. His institution performs research with Grants from Novartis. PAF has received honoraria from Novartis, Amgen, Pfizer, Roche, Teva, Celgene, Eisai, Daiichi-Sankyo and PUMA. His institution performs research with Grants from Biontech and Novartis. PG has received honoraria from Novartis, travel support from Novartis, Roche and PharmaMar. MPL has received honoraria from Novartis, AstraZeneca, Roche, Pfizer, Lilly Eisai, Genomic Health and Tesaro. The remaining authors declare that they have no conflict of interest.

Ethical approval

Approval for this retrospective study was obtained from the Ethics Committee of the Faculty of Medicine at Friedrich Alexander University of Erlangen-Nuremberg. All procedures were in accordance with the Ethical Standards of the Institutional and/or National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from each individual participant included in the study.

Supplementary material

10549_2019_5198_MOESM1_ESM.docx (5 mb)
Supplementary material 1 (DOCX 5131 KB)

References

  1. 1.
    Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS (2003) Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21:241–250.  https://doi.org/10.1200/JCO.2003.05.044 CrossRefGoogle Scholar
  2. 2.
    Andre F, Arnedos M, Goubar A, Ghouadni A, Delaloge S (2015) Ki67—no evidence for its use in node-positive breast cancer. Nat Rev Clin Oncol 12:296–301.  https://doi.org/10.1038/nrclinonc.2015.46 CrossRefGoogle Scholar
  3. 3.
    Beckmann MW, Brucker C, Hanf V, Rauh C, Bani MR, Knob S, Petsch S, Schick S, Fasching PA, Hartmann A, Lux MP, Haberle L (2011) Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients. Onkologie 34:362–367.  https://doi.org/10.1159/000329601 CrossRefGoogle Scholar
  4. 4.
    Boros M, Moncea D, Moldovan C, Podoleanu C, Georgescu R, Stolnicu S (2017) Intratumoral heterogeneity for Ki-67 index in invasive breast carcinoma: a study on 131 consecutive cases. Appl Immunohistochem Mol Morphol 25:338–340.  https://doi.org/10.1097/PAI.0000000000000315 CrossRefGoogle Scholar
  5. 5.
    Caldarella A, Crocetti E, Paci E (2014) Ki67 in breast cancer: a useful prognostic marker? Ann Oncol 25:542.  https://doi.org/10.1093/annonc/mdt561 CrossRefGoogle Scholar
  6. 6.
    Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M, MINDACT Investigators (2016) 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375:717–729.  https://doi.org/10.1056/NEJMoa1602253 CrossRefGoogle Scholar
  7. 7.
    Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750.  https://doi.org/10.1093/jnci/djp082 CrossRefGoogle Scholar
  8. 8.
    NCT02513394 (2015) PALbociclib CoLlaborative Adjuvant Study: a randomized Phase III Trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (PALLAS). NIH U.S. National Library of Medicine. http://clinicaltrials.gov. Accessed 17 Nov 2018
  9. 9.
    NCT03155997 (2017) Endocrine therapy with or without abemaciclib (LY2835219) following surgery in participants with breast cancer (monarchE). NIH U.S. National Library of Medicine. http://clinicaltrials.gov. Accessed 17 Nov 2018
  10. 10.
    NCT03701334 (2018) A trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer (NATALEE). NIH U.S. National Library of Medicine. http://clinicaltrials.gov. Accessed 17 Nov 2018
  11. 11.
    Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172.  https://doi.org/10.1016/S0140-6736(13)62422-8 CrossRefGoogle Scholar
  12. 12.
    Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29:4273–4278.  https://doi.org/10.1200/JCO.2010.31.2835 CrossRefGoogle Scholar
  13. 13.
    Denkert C, Loibl S, Muller BM, Eidtmann H, Schmitt WD, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Rudiger T, Erbstosser E, Blohmer JU, Budczies J, Mehta KM, von Minckwitz G (2013) Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 24:2786–2793.  https://doi.org/10.1093/annonc/mdt350 CrossRefGoogle Scholar
  14. 14.
    Dieras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS (2018) Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+/HER2− advanced breast cancer. J Natl Cancer Inst.  https://doi.org/10.1093/jnci/djy109 Google Scholar
  15. 15.
    Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF, International Ki-67 in Breast Cancer Working Group (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 103:1656–1664.  https://doi.org/10.1093/jnci/djr393 CrossRefGoogle Scholar
  16. 16.
    Early Breast Cancer Trialists’ Collaborative Group, Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444.  https://doi.org/10.1016/S0140-6736(11)61625-5 CrossRefGoogle Scholar
  17. 17.
    Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR, Schrauder M, Kahmann L, Lux MP, Strehl JD, Hartmann A, Dimmler A, Beckmann MW, Wachter DL (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11:486.  https://doi.org/10.1186/1471-2407-11-486 CrossRefGoogle Scholar
  18. 18.
    Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, Huober J, Liedtke C, Weinshilboum RM, Wang L, Ingle JN, Muller V, Nekljudova V, Weber KE, Rack B, Rubner M, von Minckwitz G, Couch FJ (2018) BRCA1/2 mutations and bevacizumab in the neoadjuvant treatment of breast cancer: response and prognosis results in patients with triple-negative breast cancer from the GeparQuinto Study. J Clin Oncol 36:2281–2287.  https://doi.org/10.1200/JCO.2017.77.2285 CrossRefGoogle Scholar
  19. 19.
    Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25–35.  https://doi.org/10.1016/S1470-2045(14)71159-3 CrossRefGoogle Scholar
  20. 20.
    Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ (2009) PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11:R77.  https://doi.org/10.1186/bcr2419 CrossRefGoogle Scholar
  21. 21.
    Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Dieras V, Slamon DJ (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925–1936.  https://doi.org/10.1056/NEJMoa1607303 CrossRefGoogle Scholar
  22. 22.
    Focke CM, Decker T, van Diest PJ (2016) Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours. Histopathology 69:849–861.  https://doi.org/10.1111/his.13007 CrossRefGoogle Scholar
  23. 23.
    Gass P, Lux MP, Rauh C, Hein A, Bani MR, Fiessler C, Hartmann A, Haberle L, Pretscher J, Erber R, Wachter DL, Schulz-Wendtland R, Beckmann MW, Fasching PA, Wunderle M (2018) Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer 18:1051.  https://doi.org/10.1186/s12885-018-4925-1 CrossRefGoogle Scholar
  24. 24.
    Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35:3638–3646.  https://doi.org/10.1200/JCO.2017.75.6155 CrossRefGoogle Scholar
  25. 25.
    Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel m (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223.  https://doi.org/10.1093/annonc/mdt303 CrossRefGoogle Scholar
  26. 26.
    Himuro T, Horimoto Y, Arakawa A, Tanabe M, Saito M (2016) Ki67 heterogeneity in estrogen receptor-positive breast cancers: which tumor type has the most heterogeneity? Int J Surg Pathol 24:103–107.  https://doi.org/10.1177/1066896915605179 CrossRefGoogle Scholar
  27. 27.
    Jang MH, Kim HJ, Chung YR, Lee Y, Park SY (2017) A comparison of Ki-67 counting methods in luminal breast cancer: the average method vs. the hot spot method. PLoS ONE 12:e0172031.  https://doi.org/10.1371/journal.pone.0172031 CrossRefGoogle Scholar
  28. 28.
    Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, Pollack A (2009) MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol 27:3177–3184.  https://doi.org/10.1200/JCO.2008.19.8267 CrossRefGoogle Scholar
  29. 29.
    Loehberg CR, Almstedt K, Jud SM, Haeberle L, Fasching PA, Hack CC, Lux MP, Thiel FC, Schrauder MG, Brunner M, Bayer CM, Hein A, Heusinger K, Heimrich J, Bani MR, Renner SP, Hartmann A, Beckmann MW, Wachter DL (2013) Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. Breast Cancer Res Treat 138:899–908.  https://doi.org/10.1007/s10549-013-2460-y CrossRefGoogle Scholar
  30. 30.
    Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Muller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Shariat SF (2009) Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 101:114–119.  https://doi.org/10.1093/jnci/djn451 CrossRefGoogle Scholar
  31. 31.
    Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M (2013) Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat 142:69–80.  https://doi.org/10.1007/s10549-013-2691-y CrossRefGoogle Scholar
  32. 32.
    Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323–1333.  https://doi.org/10.1200/JCO.2007.14.8197 CrossRefGoogle Scholar
  33. 33.
    Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G (2018) Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36:2465–2472.  https://doi.org/10.1200/JCO.2018.78.9909 CrossRefGoogle Scholar
  34. 34.
    Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35:2875–2884.  https://doi.org/10.1200/JCO.2017.73.7585 CrossRefGoogle Scholar
  35. 35.
    Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800.  https://doi.org/10.1056/NEJMra0801289 CrossRefGoogle Scholar
  36. 36.
    Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272.  https://doi.org/10.1093/jnci/djj052 CrossRefGoogle Scholar
  37. 37.
    Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379:111–121.  https://doi.org/10.1056/NEJMoa1804710 CrossRefGoogle Scholar
  38. 38.
    Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005–2014.  https://doi.org/10.1056/NEJMoa1510764 CrossRefGoogle Scholar
  39. 39.
    Sueta A, Yamamoto Y, Hayashi M, Yamamoto S, Inao T, Ibusuki M, Murakami K, Iwase H (2014) Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes? Surgery 155:927–935.  https://doi.org/10.1016/j.surg.2014.01.009 CrossRefGoogle Scholar
  40. 40.
    Taran FA, Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wockel A, Ettl J, Luftner D, Wallwiener M, Muller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Fasching PA, Fehm TN, Schutz F (2018) Update breast cancer 2018 (Part 1)—primary breast cancer and biomarkers. Geburtshilfe Frauenheilkd 78:237–245.  https://doi.org/10.1055/s-0044-101613 CrossRefGoogle Scholar
  41. 41.
    Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19:904–915.  https://doi.org/10.1016/S1470-2045(18)30292-4 CrossRefGoogle Scholar
  42. 42.
    Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Andre F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med.  https://doi.org/10.1056/NEJMoa1810527 Google Scholar
  43. 43.
    von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804.  https://doi.org/10.1200/JCO.2011.38.8595 CrossRefGoogle Scholar
  44. 44.
    Voros A, Csorgo E, Kovari B, Lazar P, Kelemen G, Rusz O, Nyari T, Cserni G (2015) Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy. Pathol Oncol Res 21:147–155.  https://doi.org/10.1007/s12253-014-9800-z CrossRefGoogle Scholar
  45. 45.
    Warth A, Cortis J, Soltermann A, Meister M, Budczies J, Stenzinger A, Goeppert B, Thomas M, Herth FJ, Schirmacher P, Schnabel PA, Hoffmann H, Dienemann H, Muley T, Weichert W (2014) Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. Br J Cancer 111:1222–1229.  https://doi.org/10.1038/bjc.2014.402 CrossRefGoogle Scholar
  46. 46.
    Wiesner FG, Magener A, Fasching PA, Wesse J, Bani MR, Rauh C, Jud S, Schrauder M, Loehberg CR, Beckmann MW, Hartmann A, Lux MP (2009) Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast 18:135–141.  https://doi.org/10.1016/j.breast.2009.02.009 CrossRefGoogle Scholar
  47. 47.
    Wockel A, Festl J, Stuber T, Brust K, Stangl S, Heuschmann PU, Albert US, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kuhn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, Konig K, Hahne A, Kreipe HH, Knoefel WT, Denkinger M, Brucker S, Luftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch HH, Schulz-Wendtland R, Hahn M, Hanf V, Muller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Holzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmuller S, Sinn HP, Dunst J, Munstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann MW, Blohmer J, Fasching PA, Lux MP, Harbeck N, Hadji P, Hauner H, Heywang-Kobrunner S, Huober J, Hubner J, Jackisch C, Loibl S, Luck HJ, von Minckwitz G, Mobus V, Muller V, Nothlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schutz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bucker A, Krockenberger M (2018) Interdisciplinary screening, diagnosis, therapy and follow-up of breast cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017)—Part 1 with recommendations for the screening, diagnosis and therapy of breast cancer. Geburtshilfe Frauenheilkd 78:927–948.  https://doi.org/10.1055/a-0646-4522 CrossRefGoogle Scholar
  48. 48.
    Wockel A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Hadji P, Tesch H, Ettl J, Luftner D, Muller V, Welslau M, Belleville E, Brucker SY, Schutz F, Fasching PA, Fehm T, Schneeweiss A, Kolberg HC (2018) Update breast cancer 2018 (Part 3)—genomics, individualized medicine and immune therapies—in the middle of a new era: prevention and treatment strategies for early breast cancer. Geburtshilfe Frauenheilkd 78:1110–1118.  https://doi.org/10.1055/s-0043-111601 CrossRefGoogle Scholar
  49. 49.
    Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11:174–183.  https://doi.org/10.1016/S1470-2045(09)70262-1 CrossRefGoogle Scholar
  50. 50.
    Zabaglo L, Salter J, Anderson H, Quinn E, Hills M, Detre S, A’Hern R, Dowsett M (2010) Comparative validation of the SP6 antibody to Ki67 in breast cancer. J Clin Pathol 63:800–804.  https://doi.org/10.1136/jcp.2010.077578 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Peter A. Fasching
    • 1
    • 2
    Email author
  • Paul Gass
    • 1
  • Lothar Häberle
    • 1
    • 3
  • Bernhard Volz
    • 1
  • Alexander Hein
    • 1
  • Carolin C. Hack
    • 1
  • Michael P. Lux
    • 1
  • Sebastian M. Jud
    • 1
  • Arndt Hartmann
    • 4
  • Matthias W. Beckmann
    • 1
  • Dennis J. Slamon
    • 2
  • Ramona Erber
    • 4
  1. 1.Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University HospitalFriedrich Alexander University of Erlangen-NurembergNurembergGermany
  2. 2.Division of Hematology/Oncology, Department of Medicine, David Geffen School of MedicineUniversity of California at Los AngelesLos AngelesUSA
  3. 3.Biostatistics Unit, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University HospitalFriedrich Alexander University of Erlangen-NurembergNurembergGermany
  4. 4.Comprehensive Cancer Center Erlangen-EMN, Institute of Pathology, Erlangen University HospitalFriedrich Alexander University of Erlangen-NurembergNurembergGermany

Personalised recommendations